2021 American Transplant Congress
Assessing the Impact of Acute Major Adverse Kidney Events on Clinical Outcomes in Heart Transplant Recipients
1Pharmacy, MUSC Health, Charleston, SC, 2Medicine, MUSC Health, Charleston, SC
*Purpose: The purpose of this study was to elucidate contributors to the Major Adverse Kidney Events at 30 days (MAKE-30) outcome in heart transplant recipients…2021 American Transplant Congress
Treatment of Biopsy-Proven Pyelonephritis of the Transplanted Kidney is Associated with Better Graft Outcomes
University of Wisconsin, Madison, WI
*Purpose: The outcomes of treatment of pyelonephritis of the transplant kidney is not known.*Methods: From 01/1998 to 12/2019, 101 patients were found to have pyelonephritis…2021 American Transplant Congress
Angiotensin II Type-1 Receptor Antibodies are Associated with Inferior Renal Allograft Survival
Renal Department, Imperial College Healthcare NHS Trust, London, United Kingdom
*Purpose: AT1R-antibodies have been implicated in antibody-mediated vascular rejection in the absence of detectable HLA donor specific antibody (DSA), in addition to cardiovascular diseases. Transplant…2021 American Transplant Congress
Outcomes of IVIG Monotherapy for Donor-Specific Antibodies After Lung Transplantation
Vanderbilt University Medical Center, Nashville, TN
*Purpose: De novo donor-specific antibodies (DSA) are a risk factor for antibody mediated rejection (AMR) and poor clinical outcomes after lung transplant (LT). Intravenous immune…2021 American Transplant Congress
Developing and Validation of a Liver Transplantation Donation After Cardiac Death Risk Index Using the UNOS Database
Division of Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: Donation after cardiac death (DCD) liver transplantation is an increasing form of organ donation. Shlegal et. al. identified seven factors predicting 1-year DCD graft…2021 American Transplant Congress
The Effect of Covid-19 on Offer Acceptance Rates by Age and Race Groups
1SRTR, Minneapolis, MN, 2Univ of San Fransico, San Francisco, CA
*Purpose: COVID-19 causes more severe complications in older patients and disproportionately leads to poor outcomes in racial minorities. High offer acceptance rates indicate better access…2021 American Transplant Congress
Assessment of Donor-Derived Cell-Free DNA Performance Characteristics Across the Spectrum of TCMR and ABMR After Kidney Transplant
*Purpose: Different donor-derived cell-free DNA (dd-cfDNA) thresholds have been reported in association with varying TCMR, ABMR and “Borderline” diagnoses. Interpretation of dd-cfDNA levels spanning active…2021 American Transplant Congress
Reducing Rejection in Pediatric Kidney Transplantation: The Improving Renal Outcomes Collaborative (iroc)
*Purpose: To study the effect of implementing a Medication Adherence Promotion System (MAPS) on acute rejection (AR) rates in 9 pediatric kidney transplant (KT) programs.*Methods:…2021 American Transplant Congress
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients
*Purpose: Bamlanivimab and casirivimab-imdevimab are authorized for emergency use treatment of mild-to-moderate COVID-19 in patients at high-risk for progression to severe disease or hospitalization. For…2021 American Transplant Congress
CEACAM1 Signaling is Essential to Elicit Tim-3 Inhibitory Regulation in Liver Transplantation
The Dumont-UCLA Transplantation Center, Los Angeles, CA
*Purpose: T cell immunoglobulin domain and mucin domain-3 (TIM-3) has been reported to induce T cell exhaustion. By alleviating hepatic ischemia-reperfusion injury, we have explored…
- « Previous Page
- 1
- …
- 118
- 119
- 120
- 121
- 122
- …
- 139
- Next Page »